470 related articles for article (PubMed ID: 32575944)
21. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Cascone T; Sepesi B; Lin HY; Kalhor N; Parra ER; Jiang M; Godoy MCB; Zhang J; Fossella FV; Tsao AS; Lam VK; Lu C; Mott FE; Simon GR; Antonoff MB; Mehran RJ; Rice DC; Behrens C; Weissferdt A; Moran C; Vaporciyan AA; Lee JJ; Swisher SG; Gibbons DL; Wistuba II; William WN; Heymach JV
Clin Cancer Res; 2020 Jul; 26(14):3525-3536. PubMed ID: 32193228
[TBL] [Abstract][Full Text] [Related]
22. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
23. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.
Feng Y; Sun W; Zhang J; Wang Y; Chen J; Liu X; Wang L; Li S; Lv C; Lu F; Zhang J; Hong Y; Xiao S; Wang T; Jiao R; Wang Z; Qi L; Li N; Yang Y; Lin D; Fang J
Thorac Cancer; 2022 Feb; 13(3):442-452. PubMed ID: 34913597
[TBL] [Abstract][Full Text] [Related]
26. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
[TBL] [Abstract][Full Text] [Related]
28. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer.
Johnson DH; Strupp J; Greco FA; Stewart J; Merrill W; Malcolm A; Hande KR; Hainsworth JD
Cancer; 1991 Sep; 68(6):1216-20. PubMed ID: 1651802
[TBL] [Abstract][Full Text] [Related]
31. The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors.
Sun X; Feng Y; Zhang B; Huang W; Zhao X; Zhang H; Yue D; Wang C
Cancer Res Treat; 2022 Oct; 54(4):1017-1029. PubMed ID: 34809413
[TBL] [Abstract][Full Text] [Related]
32. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy in stage III NSCLC.
Allen J; Jahanzeb M
J Natl Compr Canc Netw; 2008 Mar; 6(3):285-93. PubMed ID: 18377847
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H
Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513
[TBL] [Abstract][Full Text] [Related]
36. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
Wu Y; Hu L; Zhang S; Zhang H
Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
[No Abstract] [Full Text] [Related]
37. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
38. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
39. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
[TBL] [Abstract][Full Text] [Related]
40. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
Ahmed S; Birnbaum AE; Safran HP; Dipetrillo TA; Aswad BI; Ready NE; Ng T
J Thorac Oncol; 2011 Aug; 6(8):1432-4. PubMed ID: 21847062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
